|
Post by bernstein on Mar 22, 2017 15:13:09 GMT
Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign . This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL Axsome (AXSM) Market-Cap: $83 Million Cash: $50.6 Million Price:$3.60 Shares Out: 23 Million Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdfMajor Shareholders Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
|
|
|
Post by bernstein on Mar 23, 2017 14:04:32 GMT
Rebound to $5+ coming ,stock is heavily oversold and massive undervalued thanks to the small shareoffering which created this fantastic entry opp .
|
|
|
Post by omstem on Mar 23, 2017 18:28:00 GMT
Thank you Bernstein:
This looks interesting. If I remember it right, you have helped with Red Hill Pharma and Neos also in the past and they both are doing good.
Regarding this one, I just have only one concern. They have issued on Mar 20th a press note saying that they plan to raise additional additional capital and the size and terms are not yet known. DO you think it is a good idea to wait until that becomes clear?
Thanks.
|
|
|
Post by omstem on Mar 23, 2017 18:30:01 GMT
Sorry for t he above post. On 21st they have announced the size of the offering is about 3.7 MM shares at $3.74 per share. It looks like a good entry point. Thanks.
|
|
|
Post by JHam on Mar 27, 2017 13:30:34 GMT
Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign . This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GLAxsome (AXSM) Market-Cap: $83 Million Cash: $50.6 Million Price:$3.60 Shares Out: 23 Million Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdfMajor Shareholders Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70% Bernstein, thanks for bringing another interesting stock to our attention. Nice cash to MC ratio. Great that they've received SPA for the knee OA program. I am going to check this one out a bit more. Oh by the way, is there any way you can refrain from using words like the underlined above, when introducing your stocks? Don't want to give the impression in any way that we are a stock pump board. Thanks!
|
|
|
Post by bernstein on Mar 27, 2017 15:38:25 GMT
sorry buddy its just because im very optimistic about this undiscovered stock
|
|
|
Post by JHam on Mar 27, 2017 16:35:27 GMT
sorry buddy its just because im very optimistic about this undiscovered stock No prob. Sorry for being a party pooper
|
|
|
Post by JHam on Mar 27, 2017 16:42:04 GMT
It looks like the biggest potential piece of news in the near term is the P3 COAST trial data readout, but that won't happen until 3Q. I may open a small position just to get my feet wet, but wait and see what happens with RDHL in 2Q before adding a bigger position. The only problem with that is that there could be a post-offering bounce here any day.
|
|
|
Post by JHam on Mar 27, 2017 17:03:37 GMT
|
|
|
Post by JHam on Mar 27, 2017 17:06:56 GMT
Rebound to $5+ coming ,stock is heavily oversold and massive undervalued thanks to the small shareoffering which created this fantastic entry opp . Bernstein, do you know the reason why this has lost 3x it's value over the past year? Thanks.
|
|
|
Post by bernstein on Mar 27, 2017 17:25:22 GMT
There was no reason but you can see that the drop was on very low volume so i think the reason is just because this stock is unknown .
here are the latest stock market analyst ratings:
Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.
Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.
Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
|
|
|
Post by JHam on Mar 28, 2017 2:55:19 GMT
There was no reason but you can see that the drop was on very low volume so i think the reason is just because this stock is unknown . here are the latest stock market analyst ratings: Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock. Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock. Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock. Opened a small position at $3.75.
|
|
|
Post by bernstein on Mar 28, 2017 15:13:48 GMT
Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You How to Prevent your Shares Holdings from being Shorted www.contracts-for-difference.com/Borrowing-lending-shares.html
|
|
|
Post by JHam on Mar 29, 2017 1:55:29 GMT
I doubled my position at $3.85. Still very small though. Nice move today.
|
|
|
Post by bernstein on Mar 29, 2017 14:38:07 GMT
|
|
|
Post by JHam on Mar 30, 2017 8:34:31 GMT
Nice. Looking to add another chunk today if the price is right.
|
|
|
Post by bernstein on Mar 30, 2017 19:13:52 GMT
Looks like small consolidation ongoing after the move , next leg up will drive us to $5 and higher . MarketCap $95M /Cash $50M /5x Phase 3 = Definitely one of the most undervalued Biotech you can get in USA Market Cap: $92 Million Cash: $50 Million Price: 4.10 biopharmcatalyst.com/companies/company-pipeline-database#sort=companyAXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017. AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017. AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources. AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017. AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
|
|
|
Post by bernstein on Apr 3, 2017 16:26:22 GMT
Looks like tree shaking ongoing to steal more cheap shares . AXSM is definitely one of the cheapest Nasdaq biotech i ever have seen before in last 18 years .GL Market cap: $84 million Cash: $50.6 Million NEW Presentation April phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019. AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.) AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.) AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.) AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.) AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
|
|
|
Post by JHam on Apr 4, 2017 9:45:37 GMT
I like this company and do think it is undervalued. With no data readouts until 3Q I am not rushing to get at this moment, although I did open a small position just to get my feet wet.
|
|
|
Post by bernstein on Apr 5, 2017 12:36:17 GMT
|
|